Presentation Details
Title: Hepatic Functional Improvement Detected by HepQuant DuO within 120 Days of Treatment with Rencofilstat in MASH Subjects with ≥F3 Fibrosis.
Authors: SA Harrison, P Mayo, T Hobbs, C Zhao, C Canizares, R Foster, MP McRae, SM Helmke, and GT Everson
Date:
A copy of the presentation materials will be accessible on the Company’s website at www.hepionpharma.com under “Publications” in the Pipeline section.
About
The Company's lead drug candidate, rencofilstat, is a potent inhibitor of cyclophilins, which are involved in many disease processes. Rencofilstat has been shown to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental disease models and is currently in Phase 2 clinical development for the treatment of NASH. In
Hepion has created a proprietary Artificial Intelligence deep machine learning (“AI/ML”) platform designed to better understand disease processes and identify patients that are rencofilstat responders. This AI/ML has the potential to shorten development timelines and increase the observable differences between placebo and treatment groups. In addition, Hepion’s AI/ML can be used to drive its ongoing NASH and HCC clinical development programs and identify other potential therapeutic indications for cyclophilin inhibition with rencofilstat.
For further information, please contact:
Hepion Pharmaceuticals Investor Relations
732-902-4000
Source:
2024 GlobeNewswire, Inc., source